FDA 483 - Center for Translational Medicine - July 11, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Center for Translational Medicine in Minneapolis, MN, a nonclinical laboratory, revealed significant deficiencies in their study conduct and record-keeping practices. The firm failed to adequately document study data, adhere to approved protocols, establish necessary standard operating procedures, maintain a comprehensive master schedule, and properly archive study records. These issues indicate a lack of robust quality control and data integrity.
ID · f7bac46c-b8e0-4980-89f0-9442c1f9a8c7